Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30095417 | 1.00 | MAP3K5 (1.00) | MAP3K5MAP3K6 | |
| SCHEMBL29289202 | 0.92 | MAP3K5 (0.84) | MAP3K5 | |
| SCHEMBL23638618 | 0.92 | MAP3K5 (0.84) | MAP3K5 | |
| SCHEMBL23638617 | 0.90 | MAP3K5 (0.82) | MAP3K5 | |
| SCHEMBL28383916 | 0.88 | MAP3K5 (0.79) | MAP3K5 | |
| SCHEMBL28594998 | 0.88 | MAP3K5 (0.79) | MAP3K5MAP3K6 | |
| SCHEMBL28519197 | 0.87 | MAP3K5 (0.88) | MAP3K5MAP3K6 | |
| SCHEMBL28611402 | 0.87 | MAP3K5 (0.76) | MAP3K5MAP3K6 | |
| SCHEMBL23638789 | 0.85 | MAP3K5 (1.00) | MAP3K5 | |
| SCHEMBL30095500 | 0.85 | MAP3K5 (1.00) | MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109456308-B | Heterocyclic compounds as ASK inhibitors and their use | 南京圣和药业股份有限公司 | 2022-11-29 | — | — | CN | disclosed |
| US-20210213006-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | Seal Rock Therapeutics, Inc. | 2021-07-15 | — | — | US | disclosed |
| CN-109071498-B | Kinase inhibitor and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-03-30 | — | — | CN | disclosed |
| CN-109456308-A | Heterocyclic compound and its application as ASK inhibitor | 南京圣和药业股份有限公司 | 2019-03-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210213006-A1 | METHODS OF TREATING NEURODEGENERATIVE DISEASES | SNCA, MAPT, HTT | MAP3K5 158/4885MAP3K6 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.